Regulatory compliance – Page 49

Mock audit findings ignored during FDA/EMA inspection – evidence pack inspectors expect

How to Address Mock Audit Findings Before FDA/EMA Inspections During pharmaceutical manufacturing, the gap between passing a mock audit and facing an actual FDA or EMA inspection can often reveal…

Data attribution unclear during deviation investigation – inspection citation risk and mitigation

Mitigating Risks of Unclear Data Attribution During Deviation Investigations In pharmaceutical manufacturing, data reliability is paramount. The implications of unclear data attribution during a deviation investigation can lead to serious…

CAPA follow-up weak during remediation tracking – evidence pack inspectors expect

Strengthening CAPA Follow-Up During Remediation Tracking for Inspection Readiness In pharmaceutical manufacturing, a strong Corrective and Preventive Action (CAPA) process is crucial for maintaining compliance with Good Manufacturing Practice (GMP)…

Illegible entries in controlled records during record archival – inspection citation risk and mitigation

Mitigating Risks of Illegible Entries in Controlled Records During Record Archival In pharmaceutical manufacturing, maintaining the integrity of documentation is paramount. One of the critical risks that can jeopardize regulatory…

Mock audit findings ignored during FDA/EMA inspection – preventing escalation to warning letter

How to Address Mock Audit Findings Before FDA/EMA Inspections to Prevent Warning Letters In the pharmaceutical industry, the stakes are high when regulatory inspections occur. This article focuses on a…

Backdated documentation detected during record archival – GDP remediation CAPA

Addressing the Issue of Backdated Documentation in Record Archival: A Comprehensive Playbook In the fast-paced world of pharmaceutical manufacturing, maintaining documentation integrity is crucial for compliance and operational efficiency. The…

Inadequate evidence during inspection during FDA/EMA inspection – preventing escalation to warning letter

Mitigating Inadequate Evidence During FDA/EMA Inspections to Prevent Escalation Pharmaceutical manufacturing organizations frequently find themselves navigating rigorous FDA and EMA inspections, where the adequacy of evidence can determine the trajectory…

Incomplete contemporaneous recording during audit trail review – evidence pack inspectors expect

Tackling Incomplete Contemporaneous Recording During Audit Trail Review In the process of pharmaceutical manufacturing, incomplete contemporaneous recording can lead to serious compliance issues during regulatory audits. This article serves as…

Team unprepared for interviews during FDA/EMA inspection – CAPA closure verification

Addressing Team Readiness for Interviews During FDA/EMA Inspections: A Structured Playbook In the highly regulated world of pharmaceutical manufacturing, the lack of interview preparedness among team members during FDA or…

GDP errors in batch records during record archival – ALCOA+ gap analysis

Managing GDP Errors in Batch Records During Archival: A Comprehensive Playbook In today’s highly regulated pharmaceutical environment, the accuracy and integrity of batch records during archival are paramount. GDP errors…

CAPA follow-up weak during WHO audit – CAPA closure verification

Strengthening CAPA Follow-up for WHO Audits: A Practical Guide During audits, particularly those conducted by the World Health Organization (WHO), weaknesses in the Corrective and Preventive Action (CAPA) process can…

GDP errors in batch records during deviation investigation – GDP remediation CAPA

Understanding and Remediating GDP Errors in Batch Records During Deviation Investigations In pharmaceutical manufacturing, Good Documentation Practices (GDP) are essential for ensuring traceability, data integrity, and regulatory compliance. However, errors…